000186557 001__ 186557
000186557 005__ 20240229154900.0
000186557 0247_ $$2doi$$a10.1016/j.ctro.2022.100567
000186557 037__ $$aDKFZ-2023-00009
000186557 082__ $$a610
000186557 1001_ $$0P:(DE-He78)a8a8a2fe0df558db50514c1b568ca8ff$$aHoegen, Philipp$$b0$$eFirst author$$udkfz
000186557 245__ $$aStereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk
000186557 260__ $$aAmsterdam$$bElsevier$$c2023
000186557 3367_ $$2DRIVER$$aarticle
000186557 3367_ $$2DataCite$$aOutput Types/Journal article
000186557 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1672746036_7456
000186557 3367_ $$2BibTeX$$aARTICLE
000186557 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186557 3367_ $$00$$2EndNote$$aJournal Article
000186557 500__ $$a#EA:E050#LA:E050#
000186557 520__ $$aPurpose/Objective: To evaluate the potential of stereotactic magnetic resonance-guided online adaptive radiotherapy (SMART) to fulfill dose recommendations for stereotactic body radiotherapy (SBRT) of adrenal metastases and spare organs at risk (OAR). Materials and methods: In this subgroup analysis of a prospective registry trial, 22 patients with adrenal metastases were treated on a 0.35 T MR-Linac in 5–12 fractions with fraction doses of 4–10 Gy. Baseline plans were re-calculated to the anatomy of the day. These predicted plans were reoptimized to generate adapted plans. Baseline, predicted and adapted plans were compared with regard to PTV objectives, OAR constraints and published dose recommendations. Results: The cohort comprised patients with large GTV (median 36.0 cc) and PTV (median 66.6 cc) and predominantly left-sided metastases. 179 of 181 fractions (98.9 %) were adapted because of PTV and/or OAR violations. Predicted plans frequently violated PTV coverage (99.4 %) and adjacent OAR constraints (bowel: 32.9 %, stomach: 32.8 %, duodenum: 10.4 %, kidneys: 10.8 %). In the predicted plans, the volume exposed to the maximum dose was exceeded up to 16-fold in the duodenum and up to 96-fold in the spinal cord. Adapted plans significantly reduced OAR violations by 96.4 % for the bowel, 98.5 % for the stomach, 85.6 % for the duodenum and 83.3 % for the kidneys. Plan adaptation improved PTV coverage from 82.7 ± 8.1 % to 90.6 ± 4.9 % (p < 0.001). Furthermore, recently established target volume thresholds could easily be fulfilled with SMART. No toxicities > grade II occurred. Conclusion: SMART fulfills established GTV and PTV dose recommendations while simultaneously sparing organs at risk even in a challenging cohort.
000186557 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000186557 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000186557 7001_ $$00000-0001-5795-1999$$aKatsigiannopulos, Efthimios$$b1
000186557 7001_ $$aBuchele, Carolin$$b2
000186557 7001_ $$aRegnery, Sebastian$$b3
000186557 7001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b4$$udkfz
000186557 7001_ $$aSandrini, Elisabetta$$b5
000186557 7001_ $$00000-0001-5584-6909$$aRistau, Jonas$$b6
000186557 7001_ $$00000-0002-1445-1940$$aLiermann, Jakob$$b7
000186557 7001_ $$00000-0001-7087-9581$$aMeixner, Eva$$b8
000186557 7001_ $$aForster, Tobias$$b9
000186557 7001_ $$aRenkamp, C. Katharina$$b10
000186557 7001_ $$aSchlüter, Fabian$$b11
000186557 7001_ $$aRippke, Carolin$$b12
000186557 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b13$$udkfz
000186557 7001_ $$00000-0003-3139-3444$$aKlüter, Sebastian$$b14
000186557 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b15$$eLast author$$udkfz
000186557 773__ $$0PERI:(DE-600)2885426-3$$a10.1016/j.ctro.2022.100567$$gVol. 39, p. 100567 -$$p100567$$tClinical and translational radiation oncology$$v39$$x2405-6308$$y2023
000186557 909CO $$ooai:inrepo02.dkfz.de:186557$$pVDB
000186557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a8a2fe0df558db50514c1b568ca8ff$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000186557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000186557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000186557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000186557 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000186557 9141_ $$y2023
000186557 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-16
000186557 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-16
000186557 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-16
000186557 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-16
000186557 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN TRANSL RAD ONCO : 2022$$d2023-08-23
000186557 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000186557 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000186557 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000186557 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:51:10Z
000186557 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:51:10Z
000186557 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:51:10Z
000186557 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000186557 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000186557 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000186557 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000186557 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000186557 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000186557 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000186557 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000186557 980__ $$ajournal
000186557 980__ $$aVDB
000186557 980__ $$aI:(DE-He78)E050-20160331
000186557 980__ $$aI:(DE-He78)HD01-20160331
000186557 980__ $$aUNRESTRICTED